Study of Pomalidomide in Anal Cancer Precursors

PHASE2UnknownINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

March 31, 2019

Study Completion Date

December 31, 2022

Conditions
High Grade Squamous Intra-epithelial Lesion (HSIL)
Interventions
DRUG

Pomalidomide 2 MG Oral Capsule [Pomalyst]

Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.

Trial Locations (1)

2010

St Vincent's Hospital, Darlinghurst

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kirby Institute

OTHER_GOV

NCT03113942 - Study of Pomalidomide in Anal Cancer Precursors | Biotech Hunter | Biotech Hunter